Back to Journals » OncoTargets and Therapy » Volume 6
Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
Authors Hamizi S, Freyer G, Bakrin N, Henin E, Mohtaram A, Le Saux O, Falandry C
Received 30 August 2012
Accepted for publication 12 November 2012
Published 14 February 2013 Volume 2013:6 Pages 89—94
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Salima Hamizi,1 Gilles Freyer,1 Naoual Bakrin,2 Emilie Henin,3 Amina Mohtaram,1 Olivia Le Saux,1 Claire Falandry4
1Department of Medical Oncology, Lyon 1 University and Hospices Civils de Lyon, 2Department of Gynecologic Surgery, Centre Hospitalier Lyon-Sud, 3EMR 3738 Therapeutic Modeling in Oncology, Lyon 1 University, 4Department of Geronto-Oncology and Geriatrics, Centre Hospitalier Lyon-Sud, Lyon, France
Abstract: Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both early and metastatic HER2-positive breast cancer. Patients with HER2-positive early breast cancer have to be treated with trastuzumab for one year in combination with and sequentially after chemotherapy. This requires that trastuzumab is intravenously infused over 30–90 minutes every 3 weeks for one year which is time-consuming for both the patient and the health care provider. Consequently, a subcutaneous formulation of trastuzumab using a recombinant human hyaluronidase has been developed. Recombinant human hyaluronidase transiently increases absorption and dispersion in the subcutaneous space of large therapeutic proteins, such as monoclonal antibodies, allowing subcutaneous administration of trastuzumab in about 5 minutes. Thus, subcutaneous trastuzumab could represent a new treatment option that could have benefit to both the patient and the health care system. This review focuses on the development of the subcutaneous trastuzumab formulation and analyzes clinical trials assessing the pharmacokinetics, efficacy, and safety of this new formulation.
Keywords: trastuzumab, hyaluronidase, human epidermal growth factor receptor 2, breast cancer
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.